Impact of Body Mass Index on Short-Term Outcomes in Patients Undergoing Percutaneous Coronary Intervention in Newfoundland and Labrador, Canada

Table 5

Multivariate adjusted OR for vascular complications in patients undergoing PCI.

	OR	95% CI	value
Age	1.02	1.01–1.03	0.001
Male	0.69	0.55–0.86	0.001
Diabetes	0.65	0.51–0.84	0.001
Sheath size 5 Fr	0.42	0.20–0.85	0.016
Procedural GP IIb/IIIa inhibitors	1.95	1.50–2.54	0.000
Preprocedural LMWH	1.29	1.03–1.61	0.029
Closure device	0.54	0.43–0.68	0.000
Femoral access	2.98	2.00–4.45	0.000
Year, 2010	0.49	0.30–0.80	0.005
BMI (referent category is normal weight)
Overweight	1.01	0.76–1.33	0.967
Obese	0.83	0.62–1.11	0.219

Adjusted for access site, age, aspirin, BMI, closure device, diabetes, gender, GI/liver disease, LMWH in-lab, preprocedural LMWH, GP IIb/IIIa inhibitors in-lab, preprocedural GP IIb/IIIa inhibitors, preprocedural IV heparin, prior CVD, prior HF, prior PCI, sheath size, smoking status, ticlopidine/clopidogrel, and year.
BMI: body mass index; CVD: cardiovascular disease; GP: glycoprotein; HF: heart failure; LMWH: low molecular weight heparin; PCI: percutaneous coronary intervention.